Drugs / LCA-0061
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07701954 | Jun 2026 → Apr 2028 expected | atopic IgE-mediated allergic disorder | Lycia Therapeutics, Inc. | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | LCA-0061 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07701954 ↗ |
| Route | Subcutaneous | “single and multiple ascending subcutaneous doses of LCA-0061” NCT07701954 ↗ |